Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Aug 30;11(10):367.
doi: 10.21037/atm-23-903. Epub 2023 Mar 28.

Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most?

Abdulaziz Babaier  1 , Prafull Ghatage  2
Affiliations
Editorial

Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most?

Abdulaziz Babaier et al. Ann Transl Med. .
No abstract available

Keywords: Advanced ovarian cancer; KELIM score; bevacizumab; maintenance therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-23-903/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96. 10.1056/NEJMoa1103799 - DOI - PubMed
    1. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83. 10.1056/NEJMoa1104390 - DOI - PubMed
    1. Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 2015;16:928-36. 10.1016/S1470-2045(15)00086-8 - DOI - PMC - PubMed
    1. Tewari KS, Burger RA, Enserro D, et al. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol 2019;37:2317-28. 10.1200/JCO.19.01009 - DOI - PMC - PubMed
    1. You B, Robelin P, Tod M, et al. CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. Clin Cancer Res 2020;26:4625-32. 10.1158/1078-0432.CCR-20-0054 - DOI - PubMed